Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00802893 · ClinicalTrials.gov registry record · Phase 2
Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00802893: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT00802893 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00802893, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is designed to assess the safety and efficacy of twice-daily oral dosing of 6R-BH4 to improve endothelial function, reduce systolic blood pressure and reduce arterial stiffness.
Interventions
- OTHER Placebo
- DRUG 6R-BH4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Why NCT00802893 stopped before completion
NCT00802893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00802893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00802893 about?
NCT00802893 is a clinical study titled "Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction". This study is designed to assess the safety and efficacy of twice-daily oral dosing of 6R-BH4 to improve endothelial function, reduce systolic blood pressure and reduce arterial stiffness.
What is the current status of trial NCT00802893?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2008-12. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00802893?
The interventions under investigation include: Placebo (OTHER), 6R-BH4 (DRUG).
Who is sponsoring clinical trial NCT00802893?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00802893's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia